These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 17355739)

  • 1. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
    Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
    Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy.
    Wade SW; Satram-Hoang S; Nadkar A; Macarios D; Tosteson AN
    Clin Ther; 2011 Dec; 33(12):2006-15. PubMed ID: 22099387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence in patients with severe osteoporosis treated with teriparatide.
    Ziller V; Zimmermann SP; Kalder M; Ziller M; Seker-Pektas B; Hellmeyer L; Hadji P
    Curr Med Res Opin; 2010 Mar; 26(3):675-81. PubMed ID: 20078188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
    Jones TJ; Petrella RJ; Crilly R
    J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
    Bartl R; Götte S; Hadji P; Hammerschmidt T
    Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An approach to identifying osteopenic women at increased short-term risk of fracture.
    Miller PD; Barlas S; Brenneman SK; Abbott TA; Chen YT; Barrett-Connor E; Siris ES
    Arch Intern Med; 2004 May; 164(10):1113-20. PubMed ID: 15159269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
    Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
    Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.